


RealRate

PHARMACEUTICAL 2021



Matinas BioPharma Holdings Inc. Rank 74 of 402







PHARMACEUTICAL 2021



RealRate

Matinas BioPharma Holdings Inc. Rank 74 of 402

The relative strengths and weaknesses of Matinas BioPharma Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Matinas BioPharma Holdings Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 54% points. The greatest weakness of Matinas BioPharma Holdings Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 223%, being 176% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	61,555
Cost of Goods Sold	0
Intangible Assets	1,336
Liabilities, Current	3,568
Liabilities, Non-Current	3,669
Other Assets	6,552
Other Compr. Net Income	229
Other Expenses	0
Other Liabilities	0
Other Net Income	1,073
Other Revenues	845
Property and Equipment	1,524
Research and Development	14,359
Selling, General and Administrative Expense	10,006

Output Variable	Value in 1000 USD
Assets	70,967
Liabilities	7,237
Expenses	24,365
Revenues	845
Stockholders Equity	63,731
Net Income	-22,447
Comprehensive Net Income	-22,332
Economic Capital Ratio	223%

